Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Updates in IDH-Wildtype Glioblastoma.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics - 1 Oct 2022

Melhem Jawad M, Detsky Jay, Lim-Fat Mary Jane, Perry James R

Abstract excerpt

Glioblastoma is the most aggressive primary brain tumor with a poor prognosis. The 2021 WHO CNS5 classification has further stressed the importance of molecular signatures in diagnosis although therapeutic breakthroughs are still lacking. In this review article, updates on the current and novel therapies in IDH-wildtype GBM will be discussed.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Glioblastoma
Share to Isocitrate Dehydrogenase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 35641844
DOI: 10.1007/s13311-022-01251-6
PMCID: PMC9154038

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Updates in IDH-Wildtype Glioblastoma.PMID 35641844Read ↗

Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumorsSemantic proximity Read ↗

SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022).Semantic proximity Read ↗

Journal of Neuro Oncology: Diagnostic and therapeutic implications of IDH mutations in gliomas following the 2021 World Health Organization classification of CNS tumors.Semantic proximity Read ↗

Updates on the WHO diagnosis of IDH-mutant glioma.Semantic proximity Read ↗

New hints towards a precision medicine strategy for IDH wild-type glioblastoma.Semantic proximity Read ↗

Molecular profiling of CNS tumors for the treatment and management of disease.Semantic proximity Read ↗

Glioblastoma IDH-wildtype: An integrative review of pathophysiological mechanisms, diagnostic innovations, and emerging therapeutic modalities.Semantic proximity Read ↗

The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study.Semantic proximity Read ↗

Diagnostic utility of genetic alterations in distinguishing IDH-wildtype glioblastoma from lower-grade gliomas: Insight from next-generation sequencing analysis of 479 cases.Semantic proximity Read ↗

miRNAs and related genetic biomarkers according to the WHO glioma classification: From diagnosis to future therapeutic targetsSemantic proximity Read ↗

Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?Semantic proximity Read ↗

Current Opinion on Molecular Characterization for GBM Classification in Guiding Clinical Diagnosis, Prognosis, and TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.